Possible involvement of RasGRP4 in leukemogenesis

Area of Science:

• Oncology
• Molecular Biology
• Hematology

Background:

• Leukemogenesis is understood to involve two mutation classes: class I and class II.
• A previously established HF6 cell line, immortalized by a class II mutation (MLL/SEPT6), can be transformed by class I mutations like FLT3 mutants.

Purpose of the Study:

• To elucidate the molecular mechanisms of leukemogenesis, focusing on the progression from myelodysplastic syndrome (MDS) to acute leukemia.
• To identify novel class I mutations that confer factor independence to HF6 cells.

Main Methods:

• Expression-cloning of cDNA libraries from patient samples to screen for class I mutations.
• In vivo testing of candidate gene RasGRP4 using a mouse bone marrow transplantation (BMT) model.
• Co-transduction of RasGRP4 and an AML1 mutant (S291fsX300) in a mouse BMT model to assess synergistic effects.

Main Results:

• RasGRP4, a Ras activator, was identified as a candidate class I mutation in patients with MDS and related myeloid malignancies.
• Transplantation of RasGRP4-transduced bone marrow cells into mice induced various forms of leukemia (T cell, myeloid, or mixed).
• Simultaneous transduction of RasGRP4 and AML1 mutant accelerated the onset of T cell leukemia in the mouse BMT model compared to RasGRP4 alone.

Conclusions:

• RasGRP4 is identified as a gene potentially involved in leukemogenesis.
• RasGRP4 acts as a class I mutation that cooperates with AML1 mutations in promoting T cell leukemogenesis.